What happened Shares of Exelixis (EXEL 4.17%), an oncology-focused biopharmaceutical company, started sliding Monday in response to a disappointing clinical trial readout. Investors responding to results that weren't quite good enough have shaved 20.1% from the stock's price as of 11:30 a.m. EDT.
Full Answer
Is Exelixis stock a buy or sell?
Exelixis stock has received a consensus rating of buy. The average rating score is and is based on 13 buy ratings, 5 hold ratings, and 0 sell ratings. What was the 52-week low for Exelixis stock?
What was the 52-week low for Exelixis stock?
According to the current price, Exelixis is 125.53% away from the 52-week low. What was the 52-week high for Exelixis stock? The high in the last 52 weeks of Exelixis stock was 23.52. According to the current price, Exelixis is 82.78% away from the 52-week high. What are analysts forecasts for Exelixis stock?
Who is the CEO of Exelixis?
32 employees have rated Exelixis CEO Michael M. Morrissey on Glassdoor.com. Michael M. Morrissey has an approval rating of 79% among Exelixis' employees. Who are some of Exelixis' key competitors?
What are the price targets for Exelixis'stock?
7 brokerages have issued 12 month price targets for Exelixis' stock. Their forecasts range from $19.00 to $48.00. On average, they expect Exelixis' stock price to reach $28.29 in the next twelve months. This suggests a possible upside of 63.9% from the stock's current price. View Analyst Price Targets for Exelixis.
See more
Why is Exelixis stock dropping?
Shares of Exelixis (EXEL 4.34%), an oncology-focused biopharmaceutical company, started sliding Monday in response to a disappointing clinical trial readout. Investors responding to results that weren't quite good enough have shaved 20.1% from the stock's price as of 11:30 a.m. EDT.
Is Exelixis stock a buy?
Is EXELIXIS Stock a good buy in 2022, according to Wall Street analysts? The consensus among 7 Wall Street analysts covering (NASDAQ: EXEL) stock is to Strong Buy EXEL stock.
Will Exel stock go up?
The 13 analysts offering 12-month price forecasts for Exelixis Inc have a median target of 28.00, with a high estimate of 35.00 and a low estimate of 18.00. The median estimate represents a +31.27% increase from the last price of 21.33.
What type of company is Exelixis?
drug discovery companyExelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
Is Exel a good investment?
Exelixis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.
Should I buy or sell Exelixis stock right now?
7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Exelixis in the last year. There are currently 7 buy rat...
What is Exelixis' stock price forecast for 2022?
7 brokers have issued 12 month price objectives for Exelixis' shares. Their EXEL stock forecasts range from $28.00 to $42.00. On average, they anti...
How has Exelixis' stock performed in 2022?
Exelixis' stock was trading at $18.28 on January 1st, 2022. Since then, EXEL stock has decreased by 0.8% and is now trading at $18.14. View the be...
When is Exelixis' next earnings date?
Exelixis is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for Exelixis .
How were Exelixis' earnings last quarter?
Exelixis, Inc. (NASDAQ:EXEL) issued its earnings results on Tuesday, May, 10th. The biotechnology company reported $0.21 EPS for the quarter, toppi...
What guidance has Exelixis issued on next quarter's earnings?
Exelixis issued an update on its FY 2022 earnings guidance on Tuesday, June, 7th. The company provided earnings per share guidance of for the perio...
Who are Exelixis' key executives?
Exelixis' management team includes the following people: Dr. Stelios Papadopoulos Ph.D. , Co-Founder & Independent Chair of the Board (Age 74, P...
What is Michael M. Morrissey's approval rating as Exelixis' CEO?
32 employees have rated Exelixis CEO Michael M. Morrissey on Glassdoor.com . Michael M. Morrissey has an approval rating of 79% among Exelixis' em...
Who are some of Exelixis' key competitors?
Some companies that are related to Exelixis include Amgen (AMGN) , Gilead Sciences (GILD) , Vertex Pharmaceuticals (VRTX) , Regeneron Pharmaceu...
Is Exelixis stock a Buy, Sell or Hold?
Exelixis stock has received a consensus rating of buy. The average rating score is and is based on 13 buy ratings, 5 hold ratings, and 0 sell ratings.
What was the 52-week low for Exelixis stock?
The low in the last 52 weeks of Exelixis stock was 15.51. According to the current price, Exelixis is 125.53% away from the 52-week low.
What was the 52-week high for Exelixis stock?
The high in the last 52 weeks of Exelixis stock was 23.52. According to the current price, Exelixis is 82.78% away from the 52-week high.
What are analysts forecasts for Exelixis stock?
The 18 analysts offering price forecasts for Exelixis have a median target of 32.44, with a high estimate of 52.00 and a low estimate of 22.00. The...
What happened
Shares of Exelixis ( EXEL 6.65% ), an oncology-focused biopharmaceutical company, started sliding Monday in response to a disappointing clinical trial readout. Investors responding to results that weren't quite good enough have shaved 20.1% from the stock's price as of 11:30 a.m. EDT.
So what
Along with collaboration partner Ipsen ( IPSEY 0.00% ), Exelixis announced top-line results from the Cosmic-312 trial, which evaluates the use of cabozantinib in previously untreated liver cancer patients.
Now what
Exelixis and Ipsen intend to keep running the Cosmic-312 study until completion, which will probably occur in 2022. It doesn't happen often, but there's still a chance that final overall survival results from this study will redeem Cabometyx plus Tecentriq as a first-line treatment option for liver cancer.
Where is Exelixis located?
and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in Alameda, California.
What is XL092?
is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer.
Nasdaq Global Select
A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.
Environmental, Social, and Governance Rating
"B" score indicates good relative ESG performance and an above-average degree of transparency in reporting material ESG data publicly and privately. Scores range from AAA to D.
Business Summary
A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.
When will Exelixis release its results?
(Nasdaq: EXEL) announced today that its second quarter 2021 financial results will be released on Thursday, August 5, 2021 after the markets close.
Is Cabometyx approved for HCC?
For the moment, Cabometyx is approved as a treatment for first- and second-line renal cell carcinoma (RCC), as well as advanced hepatocellular carcinoma (HCC). Insider Monkey • 10 days ago.
